RPG Life Sciences Limited

RPG Life Sciences Limited (RPGLIFE) is a micro-cap Healthcare company valued at ₹4,865 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move

RPG Life Sciences Limited last traded at ₹2,923.5, sharply up 5.22% on the day.

Recent developments

On 2026-09-03, the company announced a positive deal to acquire the API business of Raghava Life Sciences, which is expected to enhance its production capabilities. On 2026-07-30, the company highlighted its plans to scale its immunosuppressant portfolio beyond ₹200 crore and expand into global markets, reflecting strategic focus on specialty pharma.

Financial performance

The company's business has grown, with annual revenue rising 8.3% year-over-year, but net profit fell 37.1% due to higher costs. The latest quarter saw revenue up 15.8% and net profit up 18.3% compared to the same quarter a year earlier, showing some improvement in profitability.

Valuation multiples

The stock trades at 42.0 times earnings, a premium to the Healthcare median of 32.0, 8.01 times book value. It yields 0.8%.

Things to watch

The company's net profit margin has dropped 11.7 percentage points to 16.3%, indicating pressure on profitability. The stock is 6.3% below its 52-week high, suggesting a pullback from recent peak levels.

Where it stands

The company has shown revenue growth over the past year and quarter, but net profit has declined significantly. The most recent quarter saw a rise in both revenue and net profit, but the net profit margin remains low. The stock is currently trading below its 52-week high.

Summarised by DocStoX's model on 2026-10-03 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.